Amarin receives national reimbursement for VAZKEPA in Austria

Amarin (AMRN) announced that Austria’s Health Authorities have approved VAZKEPA for national reimbursement to reduce the risk of cardiovascular events in adult statin-treated patients with elevated triglycerides and established cardiovascular disease (eCVD). As of April 1st 2025, VAZKEPA will be included in Austria’s Code of Reimbursement.